DSIP sleep and hormone studies
The modern sleep experiment changes the molecule. The older human experiments leave questions about both timing and mechanism. I think those details deserve equal billing.
The fusion peptide and the yeast
The 2024 mouse study starts with a modified DSIP fusion peptide engineered to cross the blood-brain barrier. Its production involved Pichia pastoris, a yeast. In male Kun-Ming mice with PCPA-induced insomnia, the fusion peptide reduced wakefulness by approximately 31% versus the model control, restored melatonin, serotonin and dopamine measures, and increased hippocampal neuron density. Anxiety- and depression-related behavioural measures also improved.
Native DSIP performed less well in the same experiment. My question shifts to the added delivery sequence: how much of the result belongs to it? The experiment concerns a particular fusion peptide in an induced mouse model, so its result cannot simply be assigned to unmodified DSIP in people.
The older human sleep pilot
In six middle-aged people with chronic insomnia in 1981, intravenous synthetic DSIP was associated with longer sleep, fewer interruptions, slightly more REM sleep and no daytime sedation. Sleep-promoting effects appeared in the second hour; the first hour brought a slight increase in arousal.
That sequence matters. A summary saying merely “improved sleep” loses an early observation that points the other way. I distrust a DSIP bedtime prediction built from six people and a night whose result changes direction; modern controlled replication is still missing. The finding remains interesting at the size and age it actually has.
ACTH, cortisol and the mechanism question
The 1989 experiment in men reported reduced ACTH-like immunoreactivity for at least three hours after intravenous DSIP, while cortisol continued its normal daily decline without a peptide effect. It is the experiment that opens peptiviopeptides, because those paired measurements are more specific than a general claim about reducing stress.
I give this short experiment room without treating the hormone effect as dependable. The broader human hormone literature includes failures to reproduce early effects, and DSIP’s proposed role in the stress axis remains incompletely validated. The 2006 critical review also found its sleep evidence weak and inconsistently reproduced, with no identified specific receptor, gene or precursor.
DSIP is a nine-amino-acid peptide, also called emideltide, first isolated from rabbit cerebral blood during electrically induced sleep. The name records an early observation. The same review explains why the intervening decades have left its physiological role unresolved.
Mouse lifespan
The 2003 study of a DSIP-containing preparation, Deltaran, in female SHR mice reported a 24.1% increase in maximum lifespan, a 17.1% extension for the last 10% of survivors, a 2.6-fold reduction in spontaneous tumour incidence and a 22.6% reduction in bone-marrow chromosome aberrations.
Maximum lifespan and survival among the last 10% describe particular parts of the survival record. I wouldn’t substitute average lifespan for either. The preparation and the female mouse strain matter too, and this line of work comes from related Russian groups with independent replication still needed. It supplies no human longevity estimate.
DSIP community reports
A large strand of DSIP community discussion consists of people noticing nothing. Among people reporting an effect, easier sleep, vivid dreams and clearer mornings coexist with headache, next-day grogginess, nausea, dizziness and inconveniently delayed effects. These are anecdotal accounts, not clinical evidence. Informal estimates that roughly half respond are not measured clinical response rates.
A dependable duration for DSIP is hard to square with those accounts taken together. A favourable night, an unpleasant following morning and a report of no effect all belong in the account; none establishes the peptide’s pharmacology.
DSIP safety and approval
DSIP has no FDA or EMA approval, and the name emideltide does not identify an approved drug product. U.S. compounded prescription care requires a licensed provider’s decision and remains separate from FDA approval. Research-only material is not intended for human consumption and carries no pharmaceutical guarantee of identity, purity, dose accuracy or sterility.
The small human sleep and hormone experiments leave long-term safety unresolved. A mechanism that remains poorly understood also leaves medication interactions difficult to predict. Combinations with sedatives, sleep aids or alcohol are untested; pregnancy, breastfeeding and significant pre-existing conditions have no established safety data.
Persistent insomnia can have treatable causes, including sleep apnoea and circadian disorders. An intriguing peptide experiment cannot evaluate those causes. The questions about Selank and DSIP together remain open for the same practical reason: there is no adequate human combination evidence here.